ClinicalTrials.gov
ClinicalTrials.gov Menu

RFA (Radiofrequency Ablation) Versus EA (Ethanol Ablation) for Predominantly Cystic Thyroid Nodules

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01778400
Recruitment Status : Unknown
Verified November 2013 by Jung Hwan Baek, Asan Medical Center.
Recruitment status was:  Enrolling by invitation
First Posted : January 29, 2013
Last Update Posted : November 11, 2013
Sponsor:
Information provided by (Responsible Party):
Jung Hwan Baek, Asan Medical Center

Brief Summary:
Ultrasound-guided ethanol ablation is an effective treatment modality for patients with cystic thyroid nodules (cystic portion > 90%); however it is less effective in predominantly cystic thyroid nodules (90% > cystic portions > 50%). The volume reduction after EA has been reported 64% - 69.8% for predominantly cystic thyroid nodules. EA is insufficient for 26% (27/103) of patients with predominantly cystic thyroid nodules. Radiofrequency ablation to patients with incompletely resolved clinical problems after EA and the mean volume reduction ratio was 92% at 6-month follow-up. It is well known that RF ablation is effective in both predominantly cystic and solid thyroid nodules. Although RF ablation has effectively treated the patients who were unsatisfactory after EA, to the best of our knowledge, no study to date has compared these two ablation techniques. Therefore investigators performed a prospective randomized study to compare single-session RF ablation and EA for treating predominantly cystic thyroid nodules.

Condition or disease Intervention/treatment Phase
Thyroid Nodule Procedure: radiofrequency ablation Procedure: Ethanol ablation Not Applicable

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Single Session Treatment of RFA Versus EA for Predominantly Cystic Thyroid Nodules: A Randomized Controlled Trial
Study Start Date : February 2013
Actual Primary Completion Date : May 2013
Estimated Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Thyroid Diseases
Drug Information available for: Thyroid
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Radiofrequency ablation
Treatment with radiofrequency ablation for the thyroid lesions and compare the results with ethanol ablation in terms of volume reduction at 6-month follow-up (primary end point).
Procedure: radiofrequency ablation
radiofrequency ablation for the treatment as a new therapy as compared with ethanol ablation as a conventional therapy
Active Comparator: Ethanol
Treatment of predominantly cystic nodule with ethanol ablation and compare these results to radiofrequency ablation in terms of volume reduction at 6-month follow-up.
Procedure: Ethanol ablation
ethanol ablation as a conventional/control therapy to be compared with a new experimental therapy--radiofrequency ablation



Primary Outcome Measures :
  1. quantitative volume reduction ratio of a thyroid lesion at six months following compared with before the ablation treatment [ Time Frame: at six months following compared with before the ablation treatment ]

Secondary Outcome Measures :
  1. binary therapeutic success rate which was defined as the proportion of patients who showed volume reduction >50%, improvement of symptomatic and cosmetic scores, and the number of major complications [ Time Frame: 6-month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with predominantly cystic thyroid nodules (90% > cystic portion > 50%)
  • reports of pressure symptoms or cosmetic problems
  • cytologic confirmation of benignancy in at least two, separate US-guided, fine-needle aspiration cytology or core needle biopsy for cystic fluid and/or a mural, solid component
  • serum levels of thyroid hormone, thyrotropin, and calcitonin within normal limits.

Exclusion Criteria:

  • nodules showing malignant features, i.e. taller than wide, spiculated margin, markedly hypoechoic, micro- or macrocalcifications, on US
  • lack of informed consent
  • less than 20 years old
  • pregnant woman

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01778400


Locations
Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of, 138-736
Sponsors and Collaborators
Asan Medical Center
Investigators
Study Chair: Jung Hwan Baek, MD Asan Medical Center

Responsible Party: Jung Hwan Baek, Associate professor, Asan Medical Center
ClinicalTrials.gov Identifier: NCT01778400     History of Changes
Other Study ID Numbers: BJH_PCYST
First Posted: January 29, 2013    Key Record Dates
Last Update Posted: November 11, 2013
Last Verified: November 2013

Keywords provided by Jung Hwan Baek, Asan Medical Center:
Ultrasound
Radiofrequency
Ethanol
Predominantly cystic thyroid nodule
Thyroid nodule
Thyroid

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Nodule
Endocrine System Diseases
Thyroid Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Ethanol
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs